Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: Madharry who wrote (408)	12/21/2004 8:01:43 AM
From: Jim Oravetz	Respond to of 523

Neurogen Announces Phase I Clinical Trial for Proprietary Insomnia Drug BRANFORD, Conn., Dec. 20 /PRNewswire-FirstCall/ -- Neurogen Corporation (Nasdaq: NRGN) today announced that it has commenced Phase I human testing of the Company's leading proprietary drug candidate for insomnia, NG2-73. The Phase I clinical trial is a randomized, double-blind, placebo-controlled evaluation in healthy volunteers of the safety and pharmacokinetics of single rising oral does of NG2-73, which selectively modulates receptors of the gamma aminobutyric (GABA) neurotransmitter system......snip phx.corporate-ir.net